EW Stock Chart & Stats
CHF68.77
CHF0.00(0.00%)
At close: 4:00 PM EDT
CHF68.77
CHF0.00(0.00%)
Day’s Range― - ―
52-Week RangeCHF66.67 - CHF68.77
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
CHF42.09B
Enterprise ValueCHF48.81K
Total Cash (Recent Filing)CHF4.25B
Total Debt (Recent Filing)CHF704.40M
Price to Earnings (P/E)51.7
BetaN/A
Next Earnings
Oct 28, 2026EPS Estimate
0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.74
Shares Outstanding576,400,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.63
Price to Book (P/B)4.82
Price to Sales (P/S)8.22
P/FCF Ratio37.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF82.69Price Target Upside20.24% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering17
EPS Forecast (FY)2.44
Revenue Forecast (FY)CHF5.50B
Bulls Say, Bears Say
Bulls Say
High Margins & ProfitabilitySustained gross margins near the high 70s and a ~21% EBIT margin indicate durable pricing power and strong product mix in implantable devices and consumables. This margin base supports reinvestment in R&D and commercialization while cushioning cyclical procedure volume swings over years.
Very Strong Balance SheetExtremely low leverage and nearly $3B in cash give Edwards financial flexibility for share buybacks, targeted M&A, or elevated R&D spend without stressing liquidity. This buffer supports multi-year product launches and weathering reimbursement or procedure-volume variability.
Expanding Product Pipeline & TMTTRapid TMTT growth and multiple regulatory/clinical milestones diversify revenue beyond TAVR. New device approvals and strong durability data expand addressable markets (mitral/tricuspid and surgical), underpinning a multi-year structural growth runway and reducing single-product concentration risk.
Bears Say
Uneven Revenue & Cash VolatilityA history of revenue dips and variable operating/free cash flow signals sensitivity to procedure volumes, hospital purchasing cycles and working-capital timing. That variability complicates long-range planning for capex, buybacks and R&D allocation, raising execution risk through cycles.
Reimbursement & Trial Outcome RiskMedicare coverage decisions and pivotal trial outcomes materially affect the addressable patient pool for TAVR/TMTT. Delay or unfavorable results would slow adoption, limit procedure volumes and constrain long-term revenue growth, making policy and clinical readouts structural growth levers.
Rising SG&A And Tax/Gaap PressureIncreased SG&A spending reduces operating leverage and could compress margins if revenue ramps slower than planned. Higher effective tax and limits on R&D credits depress GAAP profitability, reducing retained earnings and free cash flow available for strategic initiatives over multiple years.
Edwards Lifesciences News
EW FAQ
What was Edwards Lifesciences’s price range in the past 12 months?
Edwards Lifesciences lowest stock price was CHF66.67 and its highest was CHF68.77 in the past 12 months.
What is Edwards Lifesciences’s market cap?
Edwards Lifesciences’s market cap is CHF42.09B.
When is Edwards Lifesciences’s upcoming earnings report date?
Edwards Lifesciences’s upcoming earnings report date is Oct 28, 2026 which is in 61 days.
How were Edwards Lifesciences’s earnings last quarter?
Edwards Lifesciences released its earnings results on Jul 23, 2026. The company reported CHF0.629 earnings per share for the quarter, beating the consensus estimate of CHF0.599 by CHF0.03.
Is Edwards Lifesciences overvalued?
According to Wall Street analysts Edwards Lifesciences’s price is currently Undervalued.
Does Edwards Lifesciences pay dividends?
Edwards Lifesciences does not currently pay dividends.
What is Edwards Lifesciences’s EPS estimate?
Edwards Lifesciences’s EPS estimate is 0.59.
How many shares outstanding does Edwards Lifesciences have?
Edwards Lifesciences has 576,400,000 shares outstanding.
What happened to Edwards Lifesciences’s price movement after its last earnings report?
Edwards Lifesciences reported an EPS of CHF0.629 in its last earnings report, beating expectations of CHF0.599. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Edwards Lifesciences?
Currently, no hedge funds are holding shares in CH:EW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Edwards Lifesciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF82.69 (20.24% Upside)
CHF82.69 (20.24% Upside)
Blogger Sentiment
Neutral
CH:EW Sentiment 58%
Sector Average 60%
Sector Average 60%
Insider Transactions
Sold Shares
Worth $6.1M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
9.01%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.81%
Trailing 12-Months
Company Description
Edwards Lifesciences
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
EW Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted robust top-line growth led by TMTT (+44.8% YoY) and solid TAVR performance (+10.5% YoY), along with margin expansion and upgraded full-year company and segment guidance. Notable clinical and regulatory milestones (SAPIEN X4S, PROGRESS timeline, PASCAL and M3 approvals/CE Mark, COMMENCE 10-year data) underpin multi-year growth prospects. Offsetting factors include foreign exchange headwinds, higher effective tax rate and GAAP earnings impacts from R&D credit changes, higher SG&A, and tougher second-half comparables creating near-term seasonality and uncertainty. On balance, positive execution, upgraded guidance and strong pipeline/clinical evidence outweigh the near-term financial and macro headwinds.View all CH:EW earnings summariesEW Net sales Breakdown
73.96% Transcatheter Aortic Valve Replacement
9.07% Transcatheter Mitral and Tricuspid Therapies
16.96% Surgical Structural Heart
EW Stock 12 Month Forecast
Average Price Target
CHF82.69
▲(20.24% Upside)